Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled trial of TQH2722 injection in seasonal allergic rhinitis
CTR20244837Phase 2Completed
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TQH2722 in seasonal allergic rhinitis (SAR), sponsored by Nanjing Shunxin Pharmaceutical. Started Dec 2024; status: completed.
02
Drugs
TQH2722
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on CTR20244837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244837.